The Department was founded in 1973 within the framework of the 2nd Moscow Pirogov's Medical Institute, ever since 1986 the Department is incorporated into the Institute of Pharmacology.
The Department comprises the Laboratory of Pharmacogenetics, the Laboratory of Mutagenesis Pharmacology and Laboratory of Neuroprotection Pharmacology.
The Department is headed by professor Sergeui B. Seredenin (birthdate 1946), academician RAMS, USSR (1980) and RF (1998) State Prizes laureate.
tel.: (495) 601-2186
Professor Andrey D. Durnev (birthdate 1955) heads the Laboratory of Mutagenesis Pharmacology, RF State Prize laureate in 1998, correspondent member of RAMS (2007).
Òåë.: (495) 601-2189
Dr. Tatyana A. Zenina-Antipova heads the Laboratory of Neuroprotection Pharmacology.
tel. (495) 601-22-43
In 2002 a Chair of Pharmacogenetics of Russian State Medical University, Medical Biological Faculty (chaired by prof. Sergeui B. Seredenin) was founded on basis of the Department.
Major lines of scientific research:
Studies on pharmacogenetics of emotional stress responses;
Research and development of medications to prevent and correct the emotional stress responses given their hereditary determined phenotype;
Assessment of genetically controlled differences in drug metabolism;
Study on genetical regularities of formation and design&development of individual pharmacotherapy of alcoholism and drug dependence;
Evaluation of drugs mutagenic properties and elaboration of pharmacological genome protection.
Recent publications:
Effect of afobazole on the accumulation of free radical oxidation products and the catalase activity in rats with cerebral ischemia.IV Silkina, TA Zenina, SB Seredenin, and RS Mirzoian. Eksp Klin Farmakol, Jul 2006; 69(4): 47-50.[in Russ.].
Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten. IuV Vakhitova, SV Sadovnikov, RS Iamidanov, and SB Seredenin. Genetika,Jul 2006; 42(7): 968-75. [in Russ.].
Emotionality and the temporospatial organization of instantaneous EEG potentials. RG Kozhedub, EA Cheremushkin, NE Sviderskaya, SN Kozhechkin, OKh Koshtoyants, TA Korol'kova, IN Knipst, and SB Seredenin. Neurosci Behav Physiol,Jul 2006; 36(6): 663-70. [in Russ.].
Pilot clinical trial of ladasten. SA Siuniakov, SA Grishin, ES Teleshova, GG Neznamov, and SB Seredenin. Eksp Klin Farmakol,Jul 2006; 69(4): 10-5. [in Russ.].
Effect of afobazole on brain-ischemia-induced anxiety in rats. SB Seredenin, VP Akopian, MG Balasanian, and AV Topchian. Eksp Klin Farmakol,Mar 2006; 69(2): 3-5. [in Russ.].
Comutagen interaction of verapamil and ribavirin.AD Durnev, NO Daugel'-Dauge, and SB Seredenin. Eksp Klin Farmakol,Jan 2006; 69(1): 56-9. [in Russ.].
The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats. M Mikhaylova, JV Vakhitova, RS Yamidanov, MKh Salimgareeva, SB Seredenin, and T Behnisch. Neuropharmacology, October 1, 2007; 53(5): 601-8.
The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats.M Mikhaylova, JV Vakhitova, RS Yamidanov, MKh Salimgareeva, SB Seredenin, and T Behnisch. Neuropharmacology, October 1, 2007; 53(5): 601-8.
M.Yarkova, L. Kolik, S.Seredenin“Experimental pharmacogenetic evaluationof Ladasten action”. Abstract book of the Sixth Annual Pharmacogenetics inPsychiatry Meeting, New YorkUSA,April 13-14, 2007.
L.Kolik,V.Zhukov, T.Gudasheva, S.Seredenin “Theenhancement of antinociceptive effect of morphine by L-Trp-containing analogueof endogenous cholecystokinin CCK4”. Abstract book, International Narcotics Research Conference, Berlin, July 8-13, 2007,p.26.
